|
Cardiovascular disease and diabetes are significant health concerns for Australians. Heart disease is the leading cause of death in Australia. ==Cardiovascular disease== Cardiovascular disease (CVD) continues to have a major impact on the health of Australians in terms of prevalence, mortality, morbidity, burden of disease and expenditure. From 2007-08, an estimated 3.4 million Australians were diagnosed with CVD. Cardiovascular disease continues to remain Australia's leading cause of death. In 2009, 46,106 deaths in Australia were directly linked with CVD (21,935 males and 24,171 females) this figure represents a total of 33% of all deaths in Australia. It was reported in 2010, that almost 16% of the total projected burden of disease was a result of CVD. This then made individuals with CVD susceptible to co-morbid conditions later in life, making them "at risk" for depression and anxiety. The number and rate of deaths from CVD have fallen considerably from the peak levels experienced in the late 1960s and early 1970s when CVD was responsible for around 60,000 deaths annually, or roughly 55% of all deaths each year. These major gains have been attributed to a combination of research, improvements in prevention and detection of cardiovascular disease, and better clinical management of people with the disease. There is a close interrelationship between CVD and other important chronic conditions, including diabetes and chronic kidney disease.〔(AIHW website ) Accessed 21 April 2009 12.35〕 Cardiovascular disease kills one Australian every 11 minutes, and 3·4 million of the country's population are affected, with the Indigenous Australians having a 30% higher rate. In their lifetime, 1·5 million Australians are estimated to have diabetes and one in six Australians are suspected to have a stroke. The Baker IDI Heart and Diabetes Institute, based in Melbourne, is one of the most well known cardiovascular disease research institutes. One of the studies directed by an Australian-Dutch research team, led by, Karin Jandeleit-Dahm from Baker IDI and Harald Schmidt from Maastricht University, Netherlands, has identified the role of an enzyme which accelerates the development of diabetic atherosclerosis. Researchers were able to substantially reduce the development of artery plaques by suppressing or inhibiting this enzyme with a new drug, which will allow prevention and treatment of cardiovascular disease in people with diabetes. Another team, led by Bronwyn Kingwell, Head of Baker IDI's Metabolic and Vascular Physiology, have additionally found a new use for an old drug. The researchers found that after taking the standard anti-hypertensive drug Ramipril, patients with peripheral arterial disease (PAD), which restricts mobility due to leg pain, enjoyed a longer and less painful time on their feet. For some patients, this could be the difference between living independently and living under the care of others for the rest of their lives. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cardiovascular disease and diabetes in Australia」の詳細全文を読む スポンサード リンク
|